Evaluating Mechanically Engineered Stem Cell Exosomes for Treating Endometrial Injury: A Clinical Study

Inclusion Criteria: 1. Females aged 20-40 years (inclusive of boundary values); 2. Normal ovarian reserve function (criteria: AFC ≥ 7, AMH \> 1.1 ng/mL); 3. History of transcervical resection of adhesions (TCRA); 4. Received PRP treatment after TCRA; 5. At least one embryo transfer (ET) cycle in which they underwent standard ovarian stimulation (fresh cycle) or standard hormone replacement therapy (FET cycle), with an endometrial thickness of \<7 mm; 6. Planned to continue IVF/ICSI/FET-assisted conception; 7. Able to accept and adhere to treatment and follow-up and willing to sign an informed consent form. Exclusion Criteria: 1. Patients with severe systemic diseases, surgical contraindications, or cycle contraindications; 2. Patients with reproductive tract infections, genital tuberculosis, pelvic inflammatory disease, or malignant tumors of reproductive organs; 3. Patients with systemic diseases that cause uterine bleeding; 4. Patients allergic to any drugs, materials, or components used in this study; 5. Patients at high risk for hormone-dependent tumors such as breast cancer or ovarian tumors; 6. Patients with untreated submucosal fibroids of any size (FIGO 0/I/II), uterine fibroids ≥5 cm (FIGO III, IV, V, VI, VII), adenomyosis, unicornuate uterus, bicornuate uterus, or endometrial polyps; 7. Patients with hydrosalpinx ≥3 cm or hydrosalpinx of any size with significant vaginal discharge; 8. Patients with ovarian endometriotic cysts (chocolate cysts) ≥4 cm; 9. Patients who participated in other clinical trials within 3 months before surgery or during the study period; 10. Patients unable to tolerate anesthesia; 11. Patients with genetic abnormalities; 12. Other patients deemed unsuitable for participation in this study by the investigator.